BioSpace News Archive

Freeline Therapeutics Holdings plc announced that it received approval from the Nasdaq Stock Market LLC to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.

TFF Pharmaceuticals, Inc. announced the closing of its previously announced underwritten offering of 10,675,001 shares of its common stock and warrants to purchase up to 5,337,501 shares of common stock.

MDxHealth SA, a commercial-stage precision diagnostics company, provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023.

Evolent Health, Inc. announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences.

Kaiser Permanente has announced Paul Minardi, MD, as executive vice president and chief executive officer of the KP Medical Foundation — the nonprofit organization created to organize expertise, systems, resources, and standards to manage ambulatory care operations in Kaiser Permanente’s Colorado and Washington state markets.

Conformis, Inc. today announced that the first procedure with the company’s new Actera™ Hip System has been performed.

KemPharm, Inc. today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.

Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that is has exercised its firstof five exclusive, target-specific optionswith LegoChem Biosciences (LCB, KOSDAQ: 141080)for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications.

Cidara Therapeutics, Inc. announced that Institutional Shareholder Services and Glass Lewis and Co, LLC, two leading, independent proxy advisory firms, have both recommended that stockholders vote “FOR” the proposed reverse stock split at the Company’s upcoming Special Meeting of Stockholders, scheduled for Thursday, December 15, 2022 at 8:00 a.m. PST.